Top Story

FDA grants aldoxorubicin orphan drug status

October 1, 2014

CytRx Corp. announced that the FDA granted multiple orphan drug designation to aldoxorubicin for the treatment of patients with glioblastoma multiforme, small cell lung cancer and ovarian cancer.

Aldoxorubicin is a modified version of the chemotherapeutic agent doxorubicin, combined with a novel single-molecule linker that binds directly and specifically to circulating albumin. This combination allows patients to receive higher doses of doxorubicin while reducing its toxic side effects.

figure In the Journals

Effective implementation of nine-valent HPV vaccination could prevent majority of cervical cancers

October 1, 2014
Most cervical precancers appear to be caused by one of nine types of HPV, according to study results.The findings suggest an investigational nine-valent HPV vaccine…
In the Journals

Lenalidomide active in recurrent ovarian cancer

September 30, 2014
Continuous treatment with lenalidomide demonstrated activity in women with late recurrent ovarian cancer, according to results of a phase 2 study…
figure Cover StoryPublication Exclusive

Quest for clinically meaningful PFS benefit an ‘imperfect science’

HemOnc Today, September 25, 2014
Small improvements in study endpoints often serve as the foundation for drug approvals.However, a small but vocal segment of the hematology and oncology research…
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »

Filter By:

FDA News

FDA grants aldoxorubicin orphan drug status

October 1, 2014
CytRx Corp. announced that the FDA granted multiple orphan drug designation to aldoxorubicin for the treatment of patients with glioblastoma…
figure In the Journals

Effective implementation of nine-valent HPV vaccination could prevent majority of cervical cancers

October 1, 2014
Most cervical precancers appear to be caused by one of nine types of HPV, according to study results.The findings suggest an investigational…
In the Journals

Lenalidomide active in recurrent ovarian cancer

September 30, 2014
Continuous treatment with lenalidomide demonstrated activity in women with late recurrent ovarian cancer, according to results of a phase 2 study…
figure Cover Story Publication Exclusive

Quest for clinically meaningful PFS benefit an ‘imperfect science’

HemOnc Today, September 25, 2014
Small improvements in study endpoints often serve as the foundation for drug approvals.However, a small but vocal segment of the hematology and…
In the Journals Perspective

IBD showed link with cervical neoplasia

September 23, 2014
A reciprocal association existed between inflammatory bowel disease, particularly Crohn’s disease, and cervical neoplasia in a recent study.In…
figure Cover Story Publication Exclusive

Cancer treatment during pregnancy ‘a constant balancing act’

HemOnc Today, September 10, 2014
Cancer during pregnancy traditionally has been a rare phenomenon.Through the last third of the 20th century, about 1 in 1,000 pregnant women…
figure In the Journals

Prediabetes increases risks for cancers overall by up to 15%

September 8, 2014
Presence of prediabetes at baseline is associated with a 15% increased risk of cancer overall and when adjusting for BMI, 
figure In the Journals

Higher Medicaid reimbursement linked to increased cancer screening rates

September 4, 2014
State-specific increased Medicaid reimbursement for office visits was significantly associated with a greater likelihood for breast, cervical and…
FDA News

FDA grants fast track designation to motolimod for platinum-resistant ovarian cancer

September 3, 2014
The FDA granted fast track designation to VTX-2337 in combination with pegylated liposomal doxorubicin for the treatment of ovarian cancer that has…
Institution Notes

BRCA research center to present second annual prize

August 28, 2014
Mary-Claire King, PhD, will receive the second annual Basser Global Prize from the University of Pennsylvania's Basser Research Center for…
More Headlines »